WO2002090931A3 - Methods for determining the prognosis for cancer patients using tucan - Google Patents

Methods for determining the prognosis for cancer patients using tucan Download PDF

Info

Publication number
WO2002090931A3
WO2002090931A3 PCT/US2002/014487 US0214487W WO02090931A3 WO 2002090931 A3 WO2002090931 A3 WO 2002090931A3 US 0214487 W US0214487 W US 0214487W WO 02090931 A3 WO02090931 A3 WO 02090931A3
Authority
WO
WIPO (PCT)
Prior art keywords
tucan
level
prognosis
determining
patients
Prior art date
Application number
PCT/US2002/014487
Other languages
French (fr)
Other versions
WO2002090931A2 (en
Inventor
John C Reed
Original Assignee
Burnham Inst
John C Reed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnham Inst, John C Reed filed Critical Burnham Inst
Priority to CA002446825A priority Critical patent/CA2446825A1/en
Priority to EP02736682A priority patent/EP1456645B1/en
Priority to AU2002309668A priority patent/AU2002309668A1/en
Priority to JP2002588143A priority patent/JP4256169B2/en
Priority to DE60221151T priority patent/DE60221151T2/en
Publication of WO2002090931A2 publication Critical patent/WO2002090931A2/en
Publication of WO2002090931A3 publication Critical patent/WO2002090931A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention provides methods for determining a prognosis for survival for a cancer patient. One method involves (a) measuring a level of a TUCAN in a neoplastic cell-containing sample from the cancer patient, and (b) comparing the level of TUCAN in the sample to a reference level of TUCAN, wherein a low level of TUCAN in the sample correlates with increased survival of the patient. Another method involves (a) measuring a level of TUCAN in a neoplastic cell-containing sample from the cancer patient, and (b) classifying the patient as belonging to either a first or second group of patients, wherein the first group of patients having low levels of TUCAN is classified as having an increased likelihood of survival compared to the second group of patients having high level of TUCAN.
PCT/US2002/014487 2001-05-07 2002-05-07 Methods for determining the prognosis for cancer patients using tucan WO2002090931A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002446825A CA2446825A1 (en) 2001-05-07 2002-05-07 Methods for determining the prognosis for cancer patients using tucan
EP02736682A EP1456645B1 (en) 2001-05-07 2002-05-07 Methods for determining the prognosis for cancer patients using tucan
AU2002309668A AU2002309668A1 (en) 2001-05-07 2002-05-07 Methods for determining the prognosis for cancer patients using tucan
JP2002588143A JP4256169B2 (en) 2001-05-07 2002-05-07 Method for determining the prognosis of cancer patients using TUCAN
DE60221151T DE60221151T2 (en) 2001-05-07 2002-05-07 METHOD FOR DETERMINING THE PROGNOSIS OF CANCER PATIENTS BY TUCANE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28923301P 2001-05-07 2001-05-07
US60/289,233 2001-05-07
US35693402P 2002-02-12 2002-02-12
US60/356,934 2002-02-12

Publications (2)

Publication Number Publication Date
WO2002090931A2 WO2002090931A2 (en) 2002-11-14
WO2002090931A3 true WO2002090931A3 (en) 2004-07-01

Family

ID=26965529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/014487 WO2002090931A2 (en) 2001-05-07 2002-05-07 Methods for determining the prognosis for cancer patients using tucan

Country Status (2)

Country Link
AU (1) AU2002309668A1 (en)
WO (1) WO2002090931A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2436098C2 (en) 2006-02-09 2011-12-10 Юниверсити Оф Саут Флорида Cancer detection by high bcl-2 levels

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATHAN N. ET AL.: "TUCAN, an antiapoptotic caspase-associated recruitment domain family protein overexpressed in cancer", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 34, 24 August 2001 (2001-08-24), pages 32220 - 32229, XP002977129 *
See also references of EP1456645A4 *

Also Published As

Publication number Publication date
AU2002309668A1 (en) 2002-11-18
WO2002090931A2 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
WO1999042090A3 (en) Treating cancer
WO2004030511A3 (en) Prostate cancer biomarkers
WO2004046098A3 (en) Method for predicting autoimmune diseases
WO2007050465A3 (en) Improved methods for beaming
WO2006128192A3 (en) Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
AU2003262998A1 (en) Signal search procedure for a position determination system
WO2003106964A3 (en) High throughput methods and devices for assaying analytes in a fluid sample
NZ597363A (en) Prognosis prediction for colorectal cancer
WO2005040396A3 (en) qRT-PCR ASSAY SYSTEM FOR GENE EXPRESSION PROFILING
DK1372469T3 (en) A method for determining the optical properties of a multilayered tissue
WO2003030731A3 (en) Method and apparatus for improving clinical accuracy of analyte measurements
EP1381864A4 (en) Detection of candida
WO2002008461A3 (en) A METHOD AND AN ALGORITHM FOR mRNA EXPRESSION ANALYSIS
WO2003048300A3 (en) Methods of identifying cellular target molecules
CA2510377A1 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
WO2004081521A3 (en) Methods for direct detection of individual methotrexate metabolites
WO2003000844A3 (en) Protein modification and maintenance molecules
WO2001092877A3 (en) Method of identifying and/or isolating stem cells
AU2001263943A1 (en) Method for detecting alpha-oxoaldehydes in the whole blood, blood plasma and/or serum of a patient
WO2002090931A3 (en) Methods for determining the prognosis for cancer patients using tucan
WO2004109286A3 (en) Methods for detecting and treating cancer using podocalyxin and/or endoglycan
EP1456645A4 (en) Methods for determining the prognosis for cancer patients using tucan
WO2005049861A3 (en) Method for the analysis of gynaecological cell proliferative disorders
AR043398A1 (en) METHODS OF DETERMINATION OF A CHEMOTHERAPEUTIC REGIME BASED ON THE LOSS OF HETEROCIGOSITY IN THE PLACE OF TIMIDYLATE SYNTHEASE
WO2007062142A3 (en) Method for identifying biomarkers associated with cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002588143

Country of ref document: JP

Ref document number: 2446825

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002736682

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002736682

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002736682

Country of ref document: EP